The list of owners does not include the issue registered in July 2025.
The company has outstanding warrants to management and the board of directors of 2,500,000 and to employees of Psyros Diagnostics Ltd. of 6,790,000, which can result in a total of 9,290,000 shares and can thus cause dilution.
Prolight Diagnostics’ share is traded on the Nordic Growth Market, NGM SME, under the name PRLD.